Compare ACCS & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCS | GNTA |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 34.0M |
| IPO Year | N/A | N/A |
| Metric | ACCS | GNTA |
|---|---|---|
| Price | $7.31 | $0.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | 14.5K | ★ 73.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.18 | N/A |
| Revenue Next Year | $7.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.75 | $0.71 |
| 52 Week High | $13.35 | $10.00 |
| Indicator | ACCS | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 36.49 |
| Support Level | $6.75 | $0.71 |
| Resistance Level | $8.77 | $1.70 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 53.33 | 5.62 |
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.